Drug Profile
Anti-CD22/CD19 monoclonal antibody-toxin conjugate - Galileo Research/ the University of Texas
Alternative Names: Combotox; Combotox N97ALatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator University of Texas Southwestern Medical Center
- Developer Galileo Research; University of Texas Southwestern Medical Center
- Class Antineoplastics; Drug conjugates; Immunotoxins; Monoclonal antibodies
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Precursor cell lymphoblastic leukaemia-lymphoma
- Discontinued B-cell lymphoma
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Acute-lymphoblastic-leukaemia in USA (IV, Infusion)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Acute-lymphoblastic-leukaemia(In children) in Germany (IV, Infusion)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Acute-lymphoblastic-leukaemia(In children) in USA (IV, Infusion)